Teva Pharmaceutical Industries Limited (TLV:TEVA)
10,080
+115 (1.15%)
Jun 8, 2026, 4:10 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $3.98B USD in the quarter ending March 31, 2026, with 2.34% growth. This brings the company's revenue in the last twelve months to $17.35B, up 4.41% year-over-year. In the year 2025, Teva Pharmaceutical Industries had annual revenue of $17.26B with 4.32% growth.
Revenue (ttm)
$17.35B
Revenue Growth
+4.41%
P/S Ratio
2.14
Revenue / Employee
$528.26K
Employees
32,842
Market Cap
117.04B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Kamada | 573.62M |
| Rekah Pharmaceutical Industry | 304.15M |
| Seach Medical Group | 275.29M |
| InterCure | 270.20M |
| Together Pharma | 109.63M |
| Tikun Olam-Cannbit Pharmaceuticals | 9.10M |
| Nextage Therapeutics | 243.00K |
Teva Pharmaceutical Industries News
- 1 hour ago - Teva's Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care - GlobeNewsWire
- 2 days ago - TEVA Unveils Positive Results in Real-World Study of AUSTEDO for Huntington's Disease - GuruFocus
- 2 days ago - 3 Generic Drug Stocks to Watch as New Growth Drivers Emerge - Nasdaq
- 2 days ago - Teva announces new data on AUSTEDO tablets, AUSTEDO XR tablets - TheFly
- 2 days ago - Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington’s Disease Chorea - Financial Post
- 2 days ago - Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea - GlobeNewsWire
- 3 days ago - Teva (TEVA) Launches New Biosimilar Ahzantive in Europe - GuruFocus
- 4 days ago - Teva launches Ahzantive in Europe - TheFly